These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34876673)

  • 21. Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models.
    Schönfeld K; Herbener P; Zuber C; Häder T; Bernöster K; Uherek C; Schüttrumpf J
    Pharm Res; 2018 Apr; 35(6):118. PubMed ID: 29666962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma.
    Pan CC; Chen PC; Chou TY; Chiang H
    Hum Pathol; 2003 Nov; 34(11):1155-62. PubMed ID: 14652817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular landscape of thymic epithelial tumors.
    Prays J; Ortiz-Villalón C
    Semin Diagn Pathol; 2022 Mar; 39(2):131-136. PubMed ID: 34272124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia.
    Kaeding AJ; Barwe SP; Gopalakrishnapillai A; Ries RE; Alonzo TA; Gerbing RB; Correnti C; Loken MR; Broderson LE; Pardo L; Le QH; Tang T; Leonti AR; Smith JL; Chou CK; Xu M; Triche T; Kornblau SM; Kolb EA; Tarlock K; Meshinchi S
    Blood Adv; 2021 May; 5(9):2350-2361. PubMed ID: 33938941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eradication of growth of HER2-positive ovarian cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse xenograft model.
    Yu L; Wang Y; Yao Y; Li W; Lai Q; Li J; Zhou Y; Kang T; Xie Y; Wu Y; Chen X; Yi C; Gou L; Yang J
    Int J Gynecol Cancer; 2014 Sep; 24(7):1158-64. PubMed ID: 24987913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thymic epithelial tumor progression in an SV40T transgenic mouse model. Cortical thymoma-thymic carcinoma sequence.
    Lee SS; Park WY; Chi JG; Seo JW; Kim JI; Kim CW; Park SH; Khang SK; Cho KJ; Seo JS; Jang JJ
    Virchows Arch; 1998 Jan; 432(1):33-42. PubMed ID: 9463585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mesothelin Expression Is Not Associated with the Presence of Cancer Stem Cell Markers SOX2 and ALDH1 in Ovarian Cancer.
    Nunes M; Pacheco F; Coelho R; Leitão D; Ricardo S; David L
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer.
    Cao B; Liu M; Huang J; Zhou J; Li J; Lian H; Huang W; Guo Y; Yang S; Lin L; Cai M; Zhi C; Wu J; Liang L; Hu Y; Hu H; He J; Liang B; Zhao Q; Zhu K
    Int J Biol Sci; 2021; 17(14):3850-3861. PubMed ID: 34671203
    [No Abstract]   [Full Text] [Related]  

  • 29. High levels of expression of Trop-2 in thymic epithelial tumors.
    Yeung V; Zaemes J; Yeh J; Giancarlo C; Ahn J; Reuss JE; Kallakury BV; Liu SV; Duttargi A; Khan G; Kim C
    Lung Cancer; 2023 Oct; 184():107324. PubMed ID: 37573703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma.
    Owen D; Chu B; Lehman AM; Annamalai L; Yearley JH; Shilo K; Otterson GA
    J Thorac Oncol; 2018 Aug; 13(8):1204-1212. PubMed ID: 29702286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Host Mesothelin Expression Increases Ovarian Cancer Metastasis in the Peritoneal Microenvironment.
    Hilliard TS; Kowalski B; Iwamoto K; Agadi EA; Liu Y; Yang J; Asem M; Klymenko Y; Johnson J; Shi Z; Marfowaa G; Yemc MG; Petrasko P; Stack MS
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.
    Liu G; Zhang Q; Liu G; Li D; Zhang L; Gu Z; Tian H; Zhang Y; Tian X
    Exp Cell Res; 2021 Dec; 409(1):112886. PubMed ID: 34673000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors.
    Serpico D; Trama A; Haspinger ER; Agustoni F; Botta L; Berardi R; Palmieri G; Zucali P; Gallucci R; Broggini M; Gatta G; Pastorino U; Pelosi G; de Braud F; Garassino MC
    Ann Oncol; 2015 May; 26(5):838-847. PubMed ID: 25411417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets.
    Enkner F; Pichlhöfer B; Zaharie AT; Krunic M; Holper TM; Janik S; Moser B; Schlangen K; Neudert B; Walter K; Migschitz B; Müllauer L
    Pathol Oncol Res; 2017 Jul; 23(3):551-564. PubMed ID: 27844328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Study on the mesothelin-specific cytotoxicity against epithelial ovarian cancer with full-length mesothelin cDNA-transduced dendritic cells.
    Wang DH; Wu XH; Qian SM; Yao HR
    Med Oncol; 2015 Apr; 32(4):116. PubMed ID: 25779534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LAT1 acts as a crucial transporter of amino acids in human thymic carcinoma cells.
    Hayashi K; Jutabha P; Maeda S; Supak Y; Ouchi M; Endou H; Fujita T; Chida M; Anzai N
    J Pharmacol Sci; 2016 Nov; 132(3):201-204. PubMed ID: 27567475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
    Hassan R; Thomas A; Alewine C; Le DT; Jaffee EM; Pastan I
    J Clin Oncol; 2016 Dec; 34(34):4171-4179. PubMed ID: 27863199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mesothelin promotes brain metastasis of non-small cell lung cancer by activating MET.
    Xia S; Duan W; Xu M; Li M; Tang M; Wei S; Lin M; Li E; Liu W; Wang Q
    J Exp Clin Cancer Res; 2024 Apr; 43(1):103. PubMed ID: 38570866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer.
    Whalen KA; White BH; Quinn JM; Kriksciukaite K; Alargova R; Au Yeung TP; Bazinet P; Brockman A; DuPont MM; Oller H; Gifford J; Lemelin CA; Lim Soo P; Perino S; Moreau B; Sharma G; Shinde R; Sweryda-Krawiec B; Bilodeau MT; Wooster R
    Mol Cancer Ther; 2019 Nov; 18(11):1926-1936. PubMed ID: 31649014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Programmed Death-ligand 1 (PD-L1) Expression in Thymic Epithelial Tumors.
    Bedekovics J; Beke L; Mokanszki A; Szilagyi S; Mehes G
    Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):1-9. PubMed ID: 30499814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.